Targeting IL-33 in chronic obstructive pulmonary disease (COPD), chronic asthma and idiopathic pulmonary fibrosis (IPF)

靶向 IL-33 治疗慢性阻塞性肺疾病 (COPD)、慢性哮喘和特发性肺纤维化 (IPF)

• 批准号: nhmrc : GNT1120152
• 负责人: Dr Chantal Donovan
• 金额: $ 31.88万
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-il-33-fibrosis-ipf/1347105
• 关键词: Targeting; IL; 33; chronic; obstructive

Lung diseases (emphysema, severe asthma & pulmonary fibrosis) are major burdens on Australian community and economy. Airway wounding is a key feature of all these diseases. Patients experience severe breathlessness seriously impacting quality of life and frequently leading to death. We will assess the potential of a new target (IL-33), & therapy (anti-IL-33) in suppressing wounding in experimental models and human tissues. This may lead to a new treatment to reverse and/or prevent lung diseases.

肺部疾病（肺气肿、严重哮喘和肺纤维化）是澳大利亚社会和经济的主要负担。气道损伤是所有这些疾病的一个关键特征。患者会经历严重的呼吸困难，严重影响生活质量，并经常导致死亡。我们将在实验模型和人体组织中评估新靶点（IL-33）和治疗（抗IL-33）在抑制损伤方面的潜力。这可能会导致一种新的治疗方法来逆转和/或预防肺部疾病。